Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Financial giants have made a conspicuous bullish move on Eli Lilly and Co. Our analysis of options history for Eli Lilly and Co (NYSE:LLY) revealed 56 unusual trades.
Delving into the details, we found 41% of traders were bullish, while 35% showed bearish tendencies. Out of all the trades we spotted, 10 were puts, with a value of $1,737,333, and 46 were calls, valued at $3,169,813.
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $300.0 and $1100.0 for Eli Lilly and Co, spanning the last three months.
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Eli Lilly and Co's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Eli Lilly and Co's whale activity within a strike price range from $300.0 to $1100.0 in the last 30 days.
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
---|---|---|---|---|---|---|---|---|---|---|---|
LLY | PUT | TRADE | BULLISH | 11/15/24 | $77.25 | $76.1 | $76.1 | $960.00 | $1.1M | 0 | 0 |
LLY | CALL | TRADE | BEARISH | 01/16/26 | $202.9 | $199.05 | $199.05 | $860.00 | $199.0K | 55 | 0 |
LLY | CALL | SWEEP | BULLISH | 01/17/25 | $63.6 | $61.4 | $62.72 | $1000.00 | $157.5K | 2.0K | 2 |
LLY | CALL | TRADE | BULLISH | 01/17/25 | $63.55 | $61.45 | $62.83 | $1000.00 | $157.0K | 2.0K | 2 |
LLY | CALL | TRADE | NEUTRAL | 01/17/25 | $63.4 | $60.75 | $61.86 | $1000.00 | $154.6K | 2.0K | 111 |
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $911.0.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Eli Lilly and Co, Benzinga Pro gives you real-time options trades alerts.
Posted In: LLY